^
Association details:
| Biomarker: | IRS2 amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | BMS-754807 (IGF-1R inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines
Excerpt:
In addition, the cell lines with KRAS mutations, those with either insulin receptor substrate 2 (IRS2) copy number gain (CNG) or higher IGF-1R expression levels, were more sensitive to the drug.
DOI:
10.1158/1535-7163.MCT-14-0794-T
